Search results
Results from the WOW.Com Content Network
Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. [10] It contains nivolumab , a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab , a lymphocyte activation gene-3 (LAG-3) blocking antibody. [ 10 ]
The trial compared Opdivo + Yervoy to standard-of-care chemotherapy as a first-line treatment for unresectable or metastatic urothelial carcinoma patients whose tumor cells express PD-L1 ≥1%.
The European Commission approved Bristol Myers Squibb & Co's (NYSE: BMY) fixed-dose combination of Opdualag (nivolumab and relatlimab) for melanoma patients aged 12 years and above. Melanoma is a ...
The FDA has accepted for review Bristol-Myers Squibb Co's (NYSE: BMY) supplemental application for Opdivo (nivolumab) plus chemotherapy for resectable non-small cell lung cancer (NSCLC) in a ...
This monoclonal antibody –related article is a stub. You can help Wikipedia by expanding it.
Bristol Myers (BMY) gets FDA approval for the Opdivo and Yervoy combination for the treatment of HCC.
Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer. [2] This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal ...
For premium support please call: 800-290-4726 more ways to reach us